Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

Mahmoud, S. A.; Ganesan, Subhashini; Naik, S V; Bissar, Safaa; Zamel, Isra Al; Warren, K N; Zaher, Walid; Khan, Gulfaraz

doi:10.1128/spectrum.00733-21

Cited by 25 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, previous studies have shown that neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infections. 23 Although a number of studies have demonstrated that the widely used Roche Elecsys anti-SARS-CoV-2 S immunoassay correlates with neutralizing anti-SARS-CoV-2 antibody assays, [24][25][26][27] we cannot completely exclude the possibility that results with other assays measuring directly neutralizing activity would differ in our cohorts.…”

Section: Discussionmentioning

confidence: 92%

Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study

Sourij

Tripolt

Aziz

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes.Materials and methods: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S immunoassay targeting the receptor-binding domain was used to quantify anti-spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination.Results: A total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes Caren Sourij, Norbert J. Tripolt and Faisal Aziz contributed equally and are joint first authors.Ivo Steinmetz and Harald Sourij contributed equally and are joint last authors.

show abstract

Section: Discussionmentioning

confidence: 92%

Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study

Sourij

Tripolt

Aziz

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…The neutralizing antibody is undoubtedly the best choice for monitoring vaccine protection, and their detection results are subject to VNT and pVNT. However, the complexity of the procedure and the length of time it takes to complete limit its widespread application ( 14 ). Relatively, CLIA is a rapid and stable method, which is widely used in the early stage of COVID-19 outbreak ( 19 ).…”

Section: Discussionmentioning

confidence: 99%

“…Currently, virus neutralization tests (VNTs) are utilized as the primary standard method for assessing neutralizing antibody levels ( 13 ), but due to their complex operations, high cost, and special facility requirements, pseudovirus neutralization tests (pVNTs) are served as substitutions for VNTs. However, neither of these two methodologies has received a widespread promotion, as the cost of performance for pVNTs is still too expensive, both in money and time, for ordinary clinics to afford ( 14 ). In contrast, CLIA provides high-throughput, rapid, and reproducible assays for neutralizing antibodies, as well as detecting trends and influencing variables in IgM, IgG, IgA, RBD, and neutralizing antibody levels after vaccination.…”

Section: Introductionmentioning

confidence: 99%

Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation

Cheng

Xue

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Levels of neutralizing antibodies (NAb) after vaccine against coronavirus disease 2019 (COVID-19) can be detected using a variety of methods. A critical challenge is how to apply simple and accurate methods to assess vaccine effect. In a population inoculated with three doses of the inactivated Sinopharm/BBIBP vaccine, we assessed the performance of chemiluminescent immunoassay (CLIA) in its implementation to detect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies, as well as the antibody kinetics of healthcare workers throughout the course of vaccination. The antibody levels of NAb, the receptor-binding-domain (RBD) antibodies and IgG peaked one month after the second and remained at a relatively high level for over three months after the booster injection, while IgM and IgA levels remained consistently low throughout the course of vaccination. The production of high-level neutralizing antibodies is more likely when the inoculation interval between the first two doses is within the range of one to two months, and that between the first and booster dose is within 230 days. CLIA showed excellent consistency and correlation between NAb, RBD, and IgG antibodies with the cytopathic effect (CPE) conventional virus neutralization test (VNT). Receiver operating characteristic (ROC) analysis revealed that the optimal cut-off levels of NAb, RBD and IgG were 61.77 AU/ml, 37.86 AU/ml and 4.64 AU/ml, with sensitivity of 0.833, 0.796 and 0.944, and specificity of 0.768, 0.750 and 0.625, respectively, which can be utilized as reliable indicators of COVID-19 vaccination immunity detection.

show abstract

“…The main characteristics of this retrospective observational SARS-CoV-2 serosurveillance study have been described elsewhere [3] . Briefly, the anti-SARS-CoV-2 spike trimeric IgG were measured with DiaSorin Trimeric spike IgG immunoassay on Liaison XL (DiaSorin, Saluggia, Italy) [4] in healthcare workers undergoing primary vaccination with Pfizer/BioNTech BNT162b2 (Pfizer Inc., New York, US; two 30 µg-doses, with 3-week interval) followed by administration of homologous vaccine booster (30 µg single-dose) more than 8 months later. Molecular testing for detecting symptomatic and asymptomatic SARS-CoV-2 infections (Seegene Allplex SARS-CoV-2 Assay; Seegene Inc., South Korea or Altona Diagnostics RealStar SARS-CoV-2 RT-PCR Kit; Altona Diagnostics GmbH, Hamburg, Germany) was conducted at 2-4 weeks intervals by nasopharyngeal swab, throughout the study.…”

Section: Methodsmentioning

confidence: 99%

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster

Salvagno¹,

Henry²,

Lippi³

2022

Infectious Diseases Now

View full text Add to dashboard Cite

Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

Abstract: Commercial serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available. This study adds new knowledge regarding the optimization of these assays for evaluating postvaccination antibodies status.

Cited by 25 publications

References 44 publications

Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study

Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study

Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster

Contact Info

Product

Resources

About